Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

ANTI-INFECTIVES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Anti-Infectives in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2006 through 2015. The report profiles 148 companies including many key and niche players worldwide such as Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma, Inc., AstraZeneca PLC , Bayer HealthCare AG , Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-Aventis SA, and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6156
Price : $3950
Companies : 148
Pages : 1123
Date : February 2010
Market Data Tables : 353

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  ANTI-INFECTIVES (Complete Report) Pages : 1123   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY120$2250
  1. MARKET OVERVIEW & DYNAMICS.....II-19 $1600  
   Introduction.....II-1
Anti-Infective Drugs – Mechanism of Action.....II-1
Increasing Drug Resistance – A Major Challenge to Reckon With.....II-1
Antibacterial Resistance Costs High.....II-1
1$100
   Novel Approaches to Combat Drug-Resistant Strains.....II-2
Combination Therapy.....II-2
New Approach to Directly Target Illness Rather than Infection.....II-2
Antivirals Directed at Human Targets.....II-2
Immunomodulation.....II-2
Antivirulence.....II-2
1$100
   Select Companies Involved in Anti-Virulence Drug Research.....II-3
Pipeline Analysis of Anti-Infectives by Therapeutic Class.....II-3
Table 1: Anti-Infectives Pipeline by Therapeutic Class and Development Stage:(includes corresponding Graph/Chart).....II-3
1$300
   Injectables Gain Traction.....II-4
Market Outlook.....II-4
Anti-Bacterials Drive Global Anti-Infectives Market.....II-4
1$100
   Table 2: World Market for Anti-Infectives (2008): Percentage Share Breakdown of Value Sales by Therapeutic Class – Anti-Bacterials, Anti-Virals, Anti-Fungals, and Others (includes corresponding Graph/Chart).....II-5
Anti-Virals – A Significant Market.....II-5
Original Brands Leads the Supreme.....II-5
Table 3: Global Market for Anti-Infectives by Licensing Status (2006-07): Percentage Share Breakdown of Value Sales for Branded, Licensed Brands, Unbranded Drugs, and Other Drugs (includes corresponding Graph/Chart).....II-5
1$300
   United States - The Largest Anti-infectives Market Globally.....II-6
Table 4: World Market for Anti-Infectives by Geographic Region (2010): Percentage Share Breakdown for US, Japan, Europe, and Rest of World (includes corresponding Graph/Chart).....II-6

Table 5: World Market for Anti-Infectives: Breakdown of Select Geographic Regions/Country by Value Growth Potential for the Period 2006-2015 (includes corresponding Graph/Chart).....II-6
Europe – The Second Leading Worldwide Market for Anti-Infectives.....II-6
1$300
   Competitive Landscape.....II-7
Table 6: Worldwide Anti-Infectives Market by Leading Players (2007): Percentage Share Breakdown of Value Sales for Glaxo SmithKline, Merck, Pfizer, Novartis, Gilead Sciences, Abbott, Wyeth, Sanofi-Aventis, Bristol-Myers Squibb, Johnson & Johnson (includes corresponding Graph/Chart).....II-7
1$300
   Table 7: Leading Anti-Infective Companies Worldwide and their Brands: Value Sales for the year 2008 (includes corresponding Graph/Chart).....II-81$300
   GlaxoSmithKline Portfolio of Anti-Infectives – Breakdown by Therapeutic Class.....II-9
1$100
  2. ANTI-BACTERIALS MARKET.....II-1012 $1100  
   Market Estimates and Forecasts.....II-10
Market Analysis by Drug Class.....II-10
Table 8: Worldwide Market for Anti-Bacterials by Major Drug Class (2008): Percentage Share Breakdown for Cephalosporins, Macrolides, Fluoroquinolones, Penicillins, and Others (includes corresponding Graph/Chart).....II-10
Market Analysis by Region.....II-10
1$300
   Competition in Anti-Bacterials Market.....II-11
Table 9: World Anti-Bacterials Market (2008): Break-Up of Value Sales (US$ Billion) for Leading Drugs (includes corresponding Graph/Chart).....II-11
1$300
   Global Market Outlook.....II-12
Antibacterial Resistance – A Key Growth Dampener.....II-12
Antibiotic-Resistant Bacteria by Type.....II-12
Bacterial Resistance to Most Commonly Used Antibacterial Drug Class: Incidence Level
  in Select Countries.....II-12
1$100
   Generic Competition Intensifies.....II-13
Patent Expiries Commoditize Antibiotics.....II-13
Patent Expiries of Major Anti-Bacterial Drugs.....II-13
1$100
   R&D Initiatives Imperative for Developing Novel Drugs to Combat Drug-Resistant
  Strains.....II-14
Hospital Market for Gram-Positive Antibacterials to Witness Encouraging Gains.....II-14
Anti-MRSA Antibiotics Find Their Way.....II-14
1$100
   What are Anti-bacterials?.....II-15
Taxonomy of Anti-bacterials.....II-15
1$100
   Classification of Anti-bacterials based on Mechanism of Action.....II-16
Antibacterial Drug Classes.....II-16
Penicillin.....II-16
Cephalosporins.....II-16
1$100
   Side Effects.....II-17
Fluroquinolones.....II-17
Side Effects.....II-17
Tetracyclines.....II-17
Treatment.....II-17
1$100
   Side Effects.....II-18
Macrolides.....II-18
Treatment.....II-18
Side Effects.....II-18
Others.....II-18
Classification based on the Process of Suppressing or Killing Bacteria.....II-18
1$100
   Bactericidal or Bacteria Destroying Drugs.....II-19
Bacteriostatic Drugs.....II-19
Bacterial Spectrum.....II-19
Use of Antibacterial Drugs: An Overview.....II-19
Phage Therapy, a Promising Approach for Bacterial Infections.....II-19
1$100
   How Does Phage Therapy Works?.....II-20
Treatment and Application of Phase Therapy.....II-20
Phages for Antibiotic-Resistant Bacteria.....II-20
1$100
   Companies Involved in Phage Therapy Research.....II-21
1$100
  3. ANTI-VIRALS MARKET.....II-2226 $1850  
   Market Estimates and Forecasts.....II-22
Five Major Anti-Virals Dominate the Antivirals Market.....II-22
Players Active in Anti-Virals Market.....II-22
1$100
   Table 10: Major Anti-Viral Drugs of GSK and Bristol-Myers Squibb: Annual Sales for the year 2008 (includes corresponding Graph/Chart).....II-23
Market Leaders In 2008: A Review.....II-23
1$300
   Table 11: World Anti-Virals Market (2008): Break-Up of Value Sales (US$ Billion) For Leading Drugs (includes corresponding Graph/Chart).....II-24
Key Trends and Issues.....II-24
Preventative Antivirals Gain Significance.....II-24
1$300
   Table 12: Global Market for Anti-Virals (2007): Percentage Share Breakdown by Category – Antiviral Therapeutics, Vaccines, Monoclonal Antibodies, and Others (includes corresponding Graph/Chart).....II-25
R&D Initiatives Abound in Antivirals Market.....II-25
Companies Involved in Late-Stage Development of Anti-virals.....II-25
1$300
   Companies Involved in Phase II Clinical Studies of Anti-virals.....II-26
Companies Involved in Phase I Clinical Studies of Anti-virals.....II-26
1$100
   Select Companies in Pre-clinical Development Phase of Anti-virals.....II-27
Development of Direct Targeted Antiviral Therapies.....II-27
New Novel Anti-Viral Peptides.....II-27
siRNA Shows Antiviral Potential.....II-27
1$100
   Combination Drug Therapy Gains Popularity.....II-28
Microbiocides, a New Way to Fight STD and HIV Infections.....II-28
1$100
   What are Anti-Virals?.....II-29
Emergence of Antivirals.....II-29
Types of Antivirals.....II-29
Entry Blockers.....II-29
1$100
   Drugs in the Market.....II-30
Viral Component Replication Blockers.....II-30
Viral Component Assimilation Blockers.....II-30
Antisense Molecules.....II-30
Synthetic Ribozymes.....II-30
1$100
   Protease Inhibitors.....II-31
Blockers for Release of Completed Viruses from the Host Cell.....II-31
Other Types of Antivirals.....II-31
Interferons.....II-31
Synthetic Monoclonal Antibodies.....II-31
1$100
   Major Viral Infections & Related Drugs.....II-32
Human Immunodeficiency Virus (HIV).....II-32
HIV Treatment – The Largest in Anti-Virals Sector.....II-32
Major Anti-HIV/AIDS Drugs by Category.....II-32
1$100
   Nucleoside Reverse Transcriptase Inhibitors (NRTIs).....II-33
Major Nucleoside Reverse Transcriptase Inhibitors (NRTIs):.....II-33
Epivir (Lamivudine).....II-33
Retrovir (Zidovudine)*.....II-33
Combivir (Epivir+Retrovir).....II-33
1$100
   Videx (Didanosine).....II-34
Zerit (Stavudine).....II-34
Hivid (Zalcitabine).....II-34
Protease Inhibitors (PIs).....II-34
Major Protease Inhibitors:.....II-34
Norvir (Ritonavir).....II-34
1$100
   Kaletra (Lopinavir+Ritonavir).....II-35
Invirase (Saquinavir).....II-35
Fosamprenavir.....II-35
Integrase Inhibitors (IIs).....II-35
ISENTRESS.....II-35
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).....II-35
Entry Blockers.....II-35
1$100
   Fusion Inhibitors.....II-36
Fuzeon (Enfuvirtide).....II-36
Antiviral siRNAs.....II-36
Drugs for HIV Infected Patients in Advanced Stage.....II-36
Combination Therapies For HIV Infected Patients.....II-36
Hepatitis Infection.....II-36
1$100
   Acute and Chronic Hepatitis Infections.....II-37
Treatment Regimen for Hepatitis Infection.....II-37
Interferons.....II-37
Standard Interferons.....II-37
1$100
   Pegylated Interferons.....II-38
Ribavirin.....II-38
Types of Hepatitis Infection based on Strains.....II-38
Hepatitis A Virus (HAV) Infection.....II-38
1$100
   Hepatitis B Virus (HBV) Infection.....II-39
Treatment for Chronic HBV Infection.....II-39
Vaccines Dominate the Category.....II-39
Antiviral Drugs for Chronic HBV Infection.....II-39
1$100
   Major Anti-HBV Drugs:.....II-40
Hepatitis C Virus (HCV) Infection.....II-40
Treatment for Chronic Hepatitis C Infection.....II-40
1$100
   Some Alternative Treatments.....II-41
Drugs in Pipeline:.....II-41
Hepatitis C - Drugs in Pipeline As on March 2008.....II-41
Hepatitis D Virus (HDV) Infection.....II-41
1$100
   Hepatitis E Virus (HEV) Infection.....II-42
Herpes Simplex Virus (HSV) Infection.....II-42
Treatment for HSV Infection.....II-42
1$100
   Major HSV Drugs Worldwide and their Patent Expiries.....II-43
Antivirals for HSV Infection.....II-43
Select HSV Infection Drugs.....II-43
Zovirax (Aciclovir).....II-43
Famvir (Famciclovir).....II-43
1$100
   Foscavir (Foscarnet).....II-44
Valtrex (Valaciclovir).....II-44
Vectavir/Denavir (Penciclovir).....II-44
Abreva (Docosanol).....II-44
Ophthalmic Viral Infections & Related Drugs.....II-44
Cytovene (Ganciclovir).....II-44
Vistide (Cidofovir).....II-44
Foscavir (Foscarnet).....II-44
1$100
   Human Papilloma Virus (HPV).....II-45
Treatment for HPV Infection.....II-45
Respiratory Viruses Infections.....II-45
Influenza Virus.....II-45
Treatment for Influenza.....II-45
1$100
   Major Influenza Drugs Profile.....II-46
Symmetrel® (Amantadine).....II-46
Flumadine (Rimantadine).....II-46
Tamiflu (Oseltamivir).....II-46
Relenza (Zanamivir).....II-46
Respiratory Syncytial Virus (RSV) Infection.....II-46
Treatment for RSV and other Respiratory Viral Infections.....II-46
Other Types of Viral Diseases.....II-46
1$100
   Treatment for Other Viral Diseases.....II-47
1$100
  4. ANTI-FUNGALS MARKET.....II-4811 $800  
   Anti-Fungals Market – A Quick Review.....II-48
Current and Future Analysis.....II-48
Anti-fungals: An Introduction.....II-48
Classification of Anti-Fungal Drugs by Class.....II-48
1$100
   Allylamines.....II-49
Select Systemic and Topical Anti-Fungal Drugs Classified under Allylamines
  Group.....II-49
Azoles.....II-49
Select Systemic and Topical Anti-Fungal Drugs Classified under Azoles Group.....II-49
1$100
   Polyene Macrolides.....II-50
Select Systemic and Topical Anti-Fungal Drugs Classified under Polyene Macrolides
  Group.....II-50
Others.....II-50
Other Systemic and Topical Anti-Fungal Drugs.....II-50
Fungal Infections & Treatment.....II-50
Aspergillosis – Disease & Symptoms.....II-50
1$100
   General Syndromes of Aspergillosis & Treatment Options.....II-51
Pulmonary Aspergillosis.....II-51
Aspergilloma.....II-51
Invasive Aspergillosis.....II-51
1$100
   Select Drugs Used for the Treatment of Invasive Aspergillosis.....II-52
Blastomycosis – Disease & Symptoms.....II-52
Blastomycosis Treatment: Azoles the Preferred Choice.....II-52
1$100
   Select Drugs or Medications Used For Blastomycosis Fungal Infection
  Treatment.....II-53
Candidiasis – Disease & Symptoms.....II-53
General Syndromes of Candidiasis & Treatment Options.....II-53
Mucocutaneous Candidiasis.....II-53
1$100
   Treatment Options.....II-541$100
   Select Drugs or Medications Used for the Treatment of Cutaneous
  Candidiasis.....II-55
Invasive Candidiasis.....II-55
1$100
   Treatment Options.....II-56
Cryptococcosis & Clinical Syndromes.....II-56
Treatment of Cryptococcosis.....II-56
1$100
   Select Drugs Used for the Treatment of Cryptococcosis.....II-57
Histoplasmosis – Disease and Symptoms.....II-57
Treatment Options for Histoplasmosis.....II-57
1$100
   Select Drugs Used for the Treatment of Histoplasmosis.....II-58
1$100
  5. AN OVERVIEW OF VACCINES MARKET.....II-597 $500  
   Introduction.....II-59
Serum Institute of India Ltd. – A Major Player in Vaccines Market.....II-59
Other Major Players Active in Vaccines Market.....II-59
1$100
   Table 13: Vaccines Portfolio of GlaxoSmithKline and Merck: Breakdown of Annual Sales (in US$ Million) for the year 2008 (includes corresponding Graph/Chart).....II-60
Select Infectious Diseases and Vaccines.....II-60
Infectious Diseases.....II-60
Diphtheria.....II-60
1$300
   Tetanus (Lockjaw).....II-61
Pertussis (Whooping Cough).....II-61
Vaccines for Diphtheria, Tetanus and Pertussis.....II-61
Select Diphtheria Vaccines by Company.....II-61
1$100
   DTaP – A Combination Vaccine for Diphtheria, Tetanus and Pertussis.....II-62
DT - A Combination Vaccine for Diphtheria and Tetanus.....II-62
Td - The Tetanus and Diphtheria Vaccine.....II-62
Tdap – A Vaccine for Tetanus, Diphtheria and Pertussis.....II-62
Measles.....II-62
1$100
   Live, Attenuated (Freeze-Dried) Measles Vaccine.....II-63
Mumps.....II-63
MMR – A Combination Vaccine for Measles, Mumps and Rubella.....II-63
Side Effects of MMR Vaccine.....II-63
1$100
   Polio & Vaccines.....II-64
Influenza Vaccines.....II-64
Hepatitis B Vaccine.....II-64
1$100
   HPV Infection Vaccines.....II-65
HIV Vaccines – Research Clipped by Lack of Funds.....II-65
1$100
  6. RESEARH & DEVELOPMENT.....II-666 $400  
   Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment.....II-66
Novartis Initiates Phase IIb Clinical Trials of Albuferon®.....II-66
Schering-Plough Concludes Phase III Trials for INTRON A® Plus REBETOL™ Combination
  Therapy.....II-66
1$100
   Progenics Advances Research on New Antibody Therapy for HIV.....II-67
Forest Labs Announces Encouraging Phase III Results of Ceftaroline.....II-67
1$100
   Pharmasset Completes Phase 1a Trial of PSI-7851, Initiates Phase1b Study.....II-68
Roche Announces Positive Results of PEGASYS/ COPEGUS Combination Therapy.....II-68
Novartis Announces Phase III Results of Menveo® Vaccine.....II-68
1$100
   Discovery Laboratories Announces Pre-Clinical Results of SURFAXIN®.....II-69
Emergent Commences Phase II Clinical Study of Typhoid Vaccine.....II-69
Enanta Begins Phase I Trial of EDP-322, the First MRSA-Active Bicyclolide.....II-69
1$100
   Roche, Pharmasset, InterMune Being Oral Anti-Virals Dual-Combination Study.....II-70
ANRS, Pharmasset, Gilead Initiate Clevudine + Viread® Clinical Trials.....II-70
2$200
  7. PRODUCT LAUNCHES.....II-724 $400  
   Rx Africa (Ethiopia) to Introduce Generic Pharmaceuticals.....II-72
Destiny Pharma Develops New Metallo-Porphyrin Anti-Bacterial Drug.....II-72
Galderma Laboratories Launches EpiduoTM Gel.....II-72
Ranbaxy Rolls Out Generic Valtrex.....II-72
1$100
   Glenmark Introduces Onabet Topical Antifungal Cream.....II-73
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin.....II-73
Watson Pharma Introduces Biaxin XL’s Generic Version.....II-73
Taisho Toyama Pharmaceutical Rolls Out Zosyn®.....II-73
1$100
   GSK Launches ALTARGO® in the UK.....II-74
Toyama Launches New Garenoxacin Quinolone Antibiotic.....II-74
Wockhardt to Introduce Cefprozil in the US.....II-74
1$100
   MSD India Launches Invanza in India.....II-75
Macrolide Antibiotic Developed in the US.....II-75
University of Michigan Devises NMR Spectroscopy for Antibiotics.....II-75
Glycopeptide-Cephalosporin Antibiotics Developed in the US.....II-75
1$100
  8. RECENT INDUSTRY ACTIVITY.....II-7617 $1100  
   Merck Merges with Schering-Plough.....II-76
Beactica and Cubist Sign Agreement.....II-76
Akela Pharma Acquires Nventa Biopharmaceuticals.....II-76
GSK and Pfizer Establish New JV for Developing Anti-HIV Drugs.....II-76
1$100
   Evotec and Cubist Ink Research Pact for Fragment-Based Drug Discovery.....II-77
Grindeks Commences Production of Anti-flu Drug, Rimantadine-Grindeks.....II-77
Galapagos Expands Partnership with GSK.....II-77
1$100
   GSK Acquires Stiefel.....II-78
The Medicines Company Acquires Targanta.....II-78
Tibotec Signs Licensing and Partnership Deal with Gilead.....II-78
1$100
   Abbott Buys Ibis Biosciences.....II-79
Elder and Strides on Expansion Mode.....II-79
Kemin Industries Acquires Amalyte Pharmaceuticals.....II-79
Valeant Pharmaceuticals International Acquires EMO-FARM.....II-79
1$100
   Pfizer Inks Agreements with Claris Lifesciences and Aurobindo Pharma.....II-80
moksha8 Extends Partnership with Roche.....II-80
Akorn Signs Agreement with Eli Lilly and Company.....II-80
Access Pharmaceuticals Acquires MacroChem.....II-80
1$100
   Vertex Pharmaceuticals Acquires ViroChem Pharma.....II-81
sanofi-aventis Acquires Laboratorios Kendrick.....II-81
DSM Enters into Joint Venture with North China Pharmaceutical Group.....II-81
1$100
   NovaBay Inks Agreement with Medical University of Innsbruck.....II-82
Tibotec Collaborates with Global Alliance for TB Drug Development.....II-82
DSM Aired Plans to Divest DSM Deretil.....II-82
1$100
   3i to Buy Alpharma Unit.....II-83
Three Rivers Acquires Infergen® HCV Drug From Valeant.....II-83
ULL Establishes New Antibiotics Unit in Himachal Pradesh.....II-83
Biocat to Expand Presence in the Indian Market.....II-83
1$100
   Ranbaxy Signs Agreement with Merck.....II-84
Zydus Acquires Controlling Interest in Simayla Pharmaceuticals.....II-84
Novartis to Acquire Protez.....II-84
1$100
   Marksans Acquires Relonchem.....II-85
Orchid Signs Licensing Agreement with Merck.....II-85
Forest and Novexel Sign Licensing Agreement.....II-85
Sanofi-aventis Collaborates with Novozymes.....II-85
1$100
   Janssen-Cilag International Obtains Marketing Authorization for INTELENCETM.....II-86
Nastech Pharmaceutical Company Changes Name to MDRNA.....II-86
Galderma Laboratories Acquires CollaGenex Pharmaceuticals.....II-86
1$100
   Emergent BioSolutions Forges Joint Venture with the University of Oxford.....II-87
Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®.....II-87
1$100
   AstraZeneca Acquires Arrow Therapeutics.....II-88
Cubist Submits INDs for CB-182,804 and CB-183,315.....II-88
1$100
   SRI International Partners with Blanca Pharmaceuticals to Develop Antibiotics.....II-89
Allergan Acquires Esprit Pharma.....II-89
GSK And Anacor Team Up for Boron Chemistry-Based Antibiotics and Antivirals.....II-89
1$100
   J&J PRD Seeks FDA Approval for Doripenem Antibiotic.....II-90
J&JPRD Seeks FDA Approval for Ceftobiprole.....II-90
GSK to Cease Sale of Amprenavir Protease Inhibitor.....II-90
1$100
   Iroko Bags Canadian Rights to Vancocin®.....II-91
AstraZeneca Purchases Biologics Production Facility from DSM Biologics.....II-91
Depomed Expands Agreement with Watson Pharmaceuticals.....II-91
Depomed Terminates Agreement with Esprit Pharma.....II-91
Phylogica and Dynamic Microbials Inks Agreement.....II-91
1$100
   Pharmasset Collaborates with University of Cincinnati.....II-92
Homeland Safety International Acquires Majority Stake in PLC Marketing.....II-92
Ecopia and Caprion Merge to Form Thallion Pharmaceuticals.....II-92
1$100
  9. DRUG APPROVALS.....II-934 $400  
   FDA Clears Extended Therapy with INTRON A in Chronic HCV Patients.....II-93
Abbott Obtains EC Approval for Kaletra® in Treating HIV Patients.....II-93
Tibotec Gets EC Clearance for PREZISTA® in Treating HIV Patients.....II-93
Health Canada Approves Anti-HIV-1 Drug, ISENTRESS®.....II-93
1$100
   Mylan Receives FDA Approval for Linezolid 600 mg Tablets.....II-94
Rottapharm/Madaus Obtains Clearance to Market ProQuin XR in Sweden.....II-94
MiddleBrook Obtains NDA Approval for MOXATAG™.....II-94
Tibotec Pharmaceuticals Obtains US FDA Approval for PREZISTA®.....II-94
Wyeth Receives an Approvable Letter from US FDA for TYGACIL®.....II-94
1$100
   Astellas Pharma Receives Approval from US FDA for MYCAMINE®.....II-95
Cubist Pharmaceuticals Receives Health Canada Approval for CUBICIN®.....II-95
Cubist Receives EC Approval for Extended Use of Cubicin®.....II-95
1$100
   GSK Receives Approval for ALTARGO® in Europe.....II-96
Cubist Gains Approval for CUBICIN in Taiwan and South Korea.....II-96
1$100
  10. FOCUS ON SELECT GLOBAL PLAYERS.....II-9712 $1000  
   Abbott Laboratories (USA).....II-97
Alcon Pharmaceuticals Ltd. (Switzerland).....II-97
1$100
   Astellas Pharma, Inc. (Japan).....II-98
AstraZeneca PLC (UK).....II-98
1$100
   Bayer HealthCare AG (Germany).....II-99
Bristol-Myers Squibb Co. (USA).....II-99
1$100
   Boehringer Ingelheim (Germany).....II-100
Cubist Pharmaceuticals, Inc. (USA).....II-100
1$100
   Daiichi Sankyo Company, Limited (Japan).....II-1011$100
   Eli Lilly and Company (USA).....II-102
Gilead Sciences, Inc. (USA).....II-102
1$100
   GlaxoSmithKline Plc (UK).....II-103
F. Hoffmann-La Roche, Ltd. (Switzerland).....II-103
1$100
   Johnson & Johnson (USA).....II-104
Merck & Co., Inc (USA).....II-104
1$100
   Novartis AG (Switzerland).....II-1051$100
   Pfizer, Inc. (USA).....II-106
Sanofi-Aventis SA (France).....II-106
1$100
   Table 14: The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart).....II-1071$300
   Wyeth Pharmaceuticals, Inc. (USA).....II-108
1$100
  11. GLOBAL MARKET PERSPECTIVE.....II-109   
   Anti-infectives by Region:.....II-109
Table 15: World Recent Past, Current & Future Analysis for Anti-Infectives by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-109
1$300
   Table 16: World 10-Year Perspective for Anti-Infectives by Geographic Region - Percentage Breakdown of Dollar Revenues for the US, Japan, Europe, and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1101$300
   Anti-Infectives by Therapeutic Class:.....II-111
Table 17: World Recent Past, Current & Future Analysis for Anti-Infectives by Therapeutic Class – Antibacterials, Antivirals, Antifungals, and Others* Markets Independently Analyzed by Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-111
1$300
   Table 18: World 10-Year Perspective for Anti-Infectives by Therapeutic Class - Percentage Breakdown of Dollar Revenues for Antibacterials, Antivirals, Antifungals, and Others* Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1121$300
   Anti-bacterials by Region:.....II-113
Table 19: World Recent Past, Current & Future Analysis for Anti-Bacterials by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-113

Table 20: World 10-Year Perspective for Anti-Bacterials by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-113
1$300
   Anti-bacterials By Drug-Class:.....II-114
Table 21: World Recent Past, Current & Future Analysis for Anti-Bacterials by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-114
1$300
   Table 22: World 10-Year Perspective for Anti-Bacterials by Drug Class - Percentage Breakdown of Annual Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-1151$300
   Table 23: World Recent Past, Current & Future Analysis for Cephalosporins by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-116

Table 24: World 10-Year Perspective for Cephalosporins by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-116
1$300
   Table 25: World Recent Past, Current & Future Analysis for Penicillins by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-117

Table 26: World 10-Year Perspective for Penicillins by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-117
1$300
   Table 27: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-118

Table 28: World 10-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-118
1$300
   Table 29: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-119

Table 30: World 10-Year Perspective for Macrolides by Geographic Region- Percentage Breakdown of Annual Sales Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-119
1$300
   Table 31: World Recent Past, Current & Future Analysis for Other Anti-bacterials by Geographic Region – US and Rest of World Markets Independently Analyzed by Annual Sales Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-120

Table 32: World 10-Year Perspective for Other Anti-bacterials by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015.....II-120
1$300
III. MARKET72$1950
  1. THE UNITED STATES.....III-123 $1225  
   A. Market Analysis.....III-1
HIV Market Perspective in the US.....III-1
HIV/AIDS - Prevalence.....III-1
1$75
   Homosexual Males – A Significant Risk Group for HIV Infections.....III-2
Women – A High Risk Group for HIV/AIDS.....III-2
African-Americans - The Leading High Risk Ethnic Group for HIV Infection.....III-2
Latinos - The Second Major Ethnic Risk Group for HIV Infection.....III-2
1$75
   An Overview of Sexually Transmitted Diseases (STDs).....III-3
Regulatory Environment.....III-3
Product Innovations/Introductions.....III-3
2$150
   Strategic Corporate Developments.....III-56$450
   FDA Regulations And Approvals.....III-112$150
   Focus on Select Players.....III-138$450
   B. Market Analytics.....III-21
Table 33: US Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-21
1$150
   Table 34: US Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class – Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-221$150
   Table 35: US 10-year Perspective for Anti-Bacterials Market by Drug Class – Percentage Breakdown of Dollars Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-23
1$150
  2. JAPAN.....III-246 $450  
   A. Market Analysis.....III-24
Infectious Disease Market Witnessing Mixed Fortunes in Japan.....III-24
HIV Infection Prevalence – One of the Lowest Worldwide.....III-24
1$75
   Hepatitis C Prevalence – Widespread and Driving the Hepatitis C Drugs
  Market.....III-25
Table 36: Leading Hepatitis C Anti-viral Products in Japan (2008(E)): Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron, and Others (includes corresponding Graph/Chart).....III-25
1$150
   Product Innovations/Introductions.....III-26
Focus on Select Players.....III-26
3$225
   B. Market Analytics.....III-29
Table 37: Japanese Recent Past, Current & Future Analysis for Anti-Infectives Market – Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
  3. EUROPE.....III-305 $375  
   A. Market Analysis.....III-30
Strategic Corporate Developments.....III-30
3$225
   B. Market Analytics.....III-33
Table 38: European Recent Past, Current & Future Analysis for Anti-Infectives Market by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Analyzed by Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-33
1$150
   Table 39: European 10-year Perspective for Anti-Infectives Market by Geographic Region – Percentage Breakdown of Dollars Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-34
1$150
  3a. FRANCE.....III-353 $225  
   A. Market Analysis.....III-35
France - The Largest Market for Anti-Infectives in Europe.....III-35
Antibiotics Use Takes A Dip, As Regulatory Authorities’ Efforts Pays Off.....III-35
Strategic Corporate Development.....III-35
1$75
   Focus on Select Players.....III-36
Sanofi-Aventis SA.....III-36
1$75
   Table 40: The below table exhibits worldwide vaccines sales of the company for the year 2008: (includes corresponding Graph/Chart).....III-37
B. Market Analytics.....III-37
Table 41: French Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-37
1$150
  3b. GERMANY.....III-383 $225  
   A. Market Analysis.....III-38
Strategic Corporate Development.....III-38
Focus on Select Players.....III-38
2$150
   B. Market Analytics.....III-40
Table 42: German Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-40
1$150
  3c. ITALY.....III-411 $150  
   Market Analysis.....III-41
Table 43: Italian Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-41
1$150
  3d. THE UNITED KINGDOM.....III-429 $675  
   A. Market Analysis.....III-42
Infectious Diseases – A Quick Primer.....III-42
Table 44: Number of new Cases, and Deaths due to Infectious Disorders in England (2006): Breakdown by Infection Type (includes corresponding Graph/Chart).....III-42
1$150
   Research and Development of New Anti-Infectives.....III-43
Table 45: Number of New Anti-Infectives Approved in UK (2003-2007): Breakdown by Therapeutic Class – Anti-Virals and Anti-Bacterials.....III-43
Impediments to the Development of New Anti-infectives.....III-43
Scientific Barriers.....III-43
1$150
   Economic Barriers.....III-44
Regulatory Barriers.....III-44
HIV/AIDS Prevalence – On the Rise.....III-44
1$75
   Drug Resistant HIV Strains - Incidence Rising.....III-45
STD – Rising Incidence Poses Health Risks.....III-45
Product Innovations/Introductions.....III-45
1$75
   Strategic Corporate Developments.....III-462$150
   Focus on Select Players.....III-482$150
   B. Market Analytics.....III-50
Table 46: UK Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-50
1$150
  3e. SPAIN.....III-511 $150  
   Market Analysis.....III-51
Table 47: Spanish Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-51
1$150
  3f. REST OF EUROPE.....III-525 $375  
   A. Market Analysis.....III-52
Focus on Select Market.....III-52
Russia – Leading the Prevalence of HIV/AIDS.....III-52
Acute Drug Supply Shortages Risk Lives HIV Victims.....III-52
Strategic Corporate Developments.....III-52
2$150
   Focus on Select Players.....III-542$150
   B. Market Analytics.....III-56
Table 48: Rest of Europe Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-56
1$150
  4. REST OF WORLD.....III-5716 $975  
   A. Market Analysis.....III-57
Focus on Select Markets.....III-57
Canada.....III-57
HIV/AIDS Prevalence.....III-57
Asia-Pacific.....III-57
HIV/AIDS Prevalence.....III-57
1$75
   HIV Infection Rising Among Male.....III-58
Australia.....III-58
HIV/AIDS Prevalence.....III-58
1$75
   Chronic Hepatitis C Prevalence.....III-59
Bangladesh.....III-59
HIV/AIDS Prevalence.....III-59
Cambodia.....III-59
HIV/AIDS Prevalence.....III-59
China.....III-59
HIV/AIDS Prevalence.....III-59
1$75
   Antibiotics Market.....III-60
Antibiotics Manufacturing.....III-60
Carbapenem Antibiotics Hold Great Potential.....III-60
1$75
   China Represents a Major Market for Hepatitis B Therapies.....III-61
India.....III-61
HIV/AIDS Prevalence.....III-61
Not-for-Profit Organizations Active in HIV/AIDS Control and Prevention.....III-61
1$75
   AIDS Control Programs for Rural Youths in India.....III-62
Anti-Infectives Market Experiencing Double- Digit Growth.....III-62
1$75
   Table 49: Pharmaceutical Market in India (2007): Percentage Market Share Breakdown by Therapeutic Class (includes corresponding Graph/Chart).....III-63
Competition.....III-63
Top 5 Drug Producers in India, and their Major Products.....III-63
Injectable Antibiotics Demonstrate Robust Growth.....III-63
1$150
   New Initiative to Develop Novel Antibiotic Molecules.....III-64
Major Players - Hepatitis B Vaccines.....III-64
Product Innovations/Introductions.....III-64
1$75
   Strategic Corporate Developments.....III-654$300
   Focus on Select Players.....III-691$75
   B. Market Analytics.....III-70
Table 50: Rest of World Recent Past, Current & Future Analysis for Anti-Infectives Market Analyzed with Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-70
1$150
   Table 51: Rest of World Recent Past, Current & Future Analysis for Anti-Bacterials Market by Drug Class - Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets Analyzed by Annual Sales Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-711$150
   Table 52: Rest of World 10-year Perspective for Anti-Bacterials Market by Drug Class – Percentage Breakdown of Dollars Sales Revenues for Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-721$150
IV. COMPETITIVE LANDSCAPE 902$995
  
Total Companies Profiled: 77 (including Divisions/Subsidiaries - 85)

Region/Country                 Players


The United States                 54    
Canada                             1
Japan                              3
Europe                            16 
     France                        2
     Germany                       3
     The United Kingdom            3
     Italy                         1
     Rest of Europe                7
Asia-Pacific (Excluding Japan)    10 
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign